Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline plc    GSK   GB0009252882

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

GlaxoSmithKline And University Of Nottingham Establish Research Center

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/26/2012 | 10:46am CET

Drug maker GlaxoSmithKline PLC (>> GlaxoSmithKline plc) and the University of Nottingham said Thursday that they formalized a collaboration to establish a new laboratory to accommodate the Centre of Excellence for sustainable chemistry and to construct an innovative carbon neutral sustainable chemistry laboratory.

MAIN FACTS:

-The Laboratory for Sustainable Chemistry is being supported by a GBP12 million grant from Glaxo.

-Shares at 0829 GMT, down 10 pence, or 0.71%, at 1,403.5 pence valuing the company at GBP71.28 million.

-By Rory Gallivan, Dow Jones Newswires; 44-20-7842-9411; rory.gallivan@dowjones.com

Stocks mentioned in the article : GlaxoSmithKline plc
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GLAXOSMITHKLINE PLC
02/24 JUSTIFICATION AND APPROVAL - 65-- RE : 00173-0681-22
02/23DJGlaxoSmithKline Reports Positive Study Results for Asthma Drug
02/23 GLAXOSMITHKLINE : Positive results for Relvar Ellipta Lung Study
02/23 GLAXOSMITHKLINE : Glaxo Gets Positive Headline Results On Relvar-Ellipta Asthma ..
02/23 GLAXOSMITHKLINE : Positive Results for Relvar® Ellipta® Lung Function Study in P..
02/23 GLAXOSMITHKLINE : Positive results for Relvar® Ellipta® lung function study in p..
02/23DJPURETECH HEALTH : Appoints Atul Pande as Chief Medical Officer
02/23 GLAXOSMITHKLINE PLC : ex-dividend day for final dividend
02/21 KORN FERRY : Futurestep Partners with GlaxoSmithKline to Support Talent Acquisit..
02/17 European shares retreat after week of gains; Allianz rallies after update
More news
Sector news : Pharmaceuticals - NEC
01:21p VALEANT PHARMACEUTICALS INTL : Pharma's revenue falls for third straight quarter
08:35aDJASTRAZENECA : FDA OKs Once-Daily Qtern for Type-2 Diabetes
02/27DJJOHNSON & JOHNSON : Prescription Unit List Prices Rose 8.5% Last Year
02/27 FTSE ends higher on some positive earnings, insurers slip
02/27DJSANOFI : Lonza to Invest CHF290 Million in New Plant in Switzerland
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
02/27 Idera Pharmaceuticals' Well-Funded And Growing Pipeline Of Potentially Blockb..
02/27 RESVERLOGIX : The Science Is Getting 'BETter' For RVX208
02/26 BIOTECH FORUM DAILY DIGEST : Can Aerie Pharmaceuticals Continue To Rally? Spotli..
02/24 I'M SICK AND TIRED OF GILEAD SCIENCE : Part 2
02/24 GILEAD : No HCV? No Problem
Advertisement
Financials ( GBP)
Sales 2017 29 950 M
EBIT 2017 8 406 M
Net income 2017 4 175 M
Debt 2017 13 538 M
Yield 2017 4,87%
P/E ratio 2017 20,35
P/E ratio 2018 17,07
EV / Sales 2017 3,15x
EV / Sales 2018 3,01x
Capitalization 80 751 M
More Financials
Chart GLAXOSMITHKLINE PLC
Duration : Period :
GlaxoSmithKline plc Technical Analysis Chart | GSK | GB0009252882 | 4-Traders
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE PLC
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 17,7  GBP
Spread / Average Target 7,6%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Andrew Philip Witty Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Dingemans Chief Financial Officer & Executive Director
Birgitte Volck Head-Research & Development
Moncef Slaoui Executive Director & Chairman-Global Vaccines
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE PLC5.28%100 411
JOHNSON & JOHNSON6.53%332 993
ROCHE HOLDING LTD.5.42%209 283
PFIZER INC.5.48%204 030
NOVARTIS AG4.72%203 039
MERCK & CO., INC.12.38%181 558
More Results